Pharmaceutical manufacturers of Hydroxychloroquine

The company was founded in 1927 by János Kabay pharmacist for manufacturing morphine from poppy head. Presently, his patent still serves as the base for industrial manufacturing of morphine all around the world.

Fermion specializes in the development, production, and promotion of active pharmaceutical ingredients (APIs) for the global generic market and exclusive contracts for new chemical entities (NCEs). It is a wholly owned subsidiary of Orion Corporation, with its headquarters in Espoo, Finland. Partnered with Orion, Fermion offers comprehensive services encompassing APIs and Formulations, including a portfolio of over 30 generic APIs and more than 10 NCEs. The manufacturing and R&D facilities are all based in Finland, with an emphasis on expanding capabilities in the production of high-potency APIs (HPAPIs). Additionally, Fermion and Orion provide a range of drug product CMO services, such as hormonal and non-hormonal semi-solids, liquids, cytotoxic oral solids, packaging, small volume parenterals, and non-cytotoxic oral solids. Orion operates three manufacturing sites and one packaging center for drug products.

MSN Group is the fastest growing research-based pharmaceutical company based out of India. Founded in 2003 with a mission to make health care affordable, this Hyderabad-based venture has Fifteen API and Six finished dosage facilities established across India & USA. The group has an integrated R&D center for both API and formulation under one roof, dedicated to research and development of pharmaceuticals to make them more accessible.

The Zydus group is based in Ahmedabad, India, and is placed 4th in the Indian pharmaceutical sector. Zydus' global operations have a substantial presence in the regulated markets of the US, Europe (specifically France and Spain), and in the prominent markets of Latin America and South Africa. It also has a significant presence in 25 other developing markets around the world.

Bringing 86 years of expertise, UQUIFA'S operational approach is built on a fusion of a high-quality production platform and a proven history of service and dependability. UQUIFA specializes in the production of Active Pharmaceutical Ingredients (APIs), Intermediates, and RSM's for the pharmaceutical and animal health sectors on a global scale. The organization runs 2 production facilities (located in Spain and Mexico) with stringent compliance to all regulatory standards. These facilities operate under cGMP conditions and have undergone evaluation and endorsement from prominent global pharmaceutical companies.

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

SCI Pharmtech Inc., founded by Switzerland-based Siegfried Ltd. in 1987, is now a public company listed at Taiwan Stock Exchange.Since 1989, SCI has satisfied worldwide customers with quality and cost- effective APIs, advanced intermediates, and custom products.Our fully equipped research laboratories, pilot and production plants and experienced staff ensure timely development and cost effective production. We work with pharmaceutical and specialty companies worldwide to develop key intermediates, APIs and custom products. Our facility is FDA,EDQM,PMDA and Taiwan TFDA inspected, designed for multi-purpose, full-scale manufacturing.

For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others.

Euroapi focuses on revolutionizing active component solutions to sustainably fulfill the demands of clients and patients globally. As a prominent figure in active pharmaceutical ingredients, we possess a comprehensive portfolio of around 200 products, encompassing a wide range of technologies, and are constantly developing innovative molecules through our Contract Development and Manufacturing Organization (CDMO). Our 3,350 employees are driven by the commitment to improving access to essential therapies and promoting health

In just over a decade, Laurus has positioned itself as one of the largest and most innovative API producers globally. Expanding upon its established expertise in chemistry, Laurus has recently adopted full vertical integration, including a strong finished dosage capacity, dedicated capacity for backward integration, and also Synthesis R&D operations in India and the USA.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Situated in Hyderabad, India, Symed Labs Ltd is a prominent and innovative producer of Active Pharmaceutical Ingredients (APIs) & a comprehensive solution provider for the pharmaceutical sector for chemistry related services. Symed labs has autonomously created processes for more than fifty APIs across various therapeutic categories in the laboratory and upscaled them to plant, as well as vending them to over 600 clients in 30 nations in the regulated and less regulated markets

Aurore Life Sciences is a specialized manufacturer of active pharmaceutical ingredients (API) with a varied range of capabilities to enhance efficiency for generic pharmaceutical companies worldwide. Established in 2017 by a team with extensive expertise throughout the pharmaceutical supply chain, the company is dedicated to becoming the most favored partner for pharmaceuticals. At Aurore, we strive to innovate in the production and delivery of dependable high-quality products, earning the trust of both customers and regulatory bodies. Our focus on rapidly expanding capabilities has driven us to acquire, integrate, and extend our presence across multiple regions.

Viyash embodies integrity and guidance in all aspects. As a fully-integrated pharmaceutical firm, we possess a robust collection of unique formulations, APIs, and advanced intermediates. Viyash and its affiliated companies manage 10 API/Intermediate facilities, boasting a combined capacity of approximately 2000 KL and diverse capabilities across various categories - small/large volume, potent/non-potent, regulated/semi-regulated markets. Additionally, we oversee a formulation manufacturing facility in New Jersey, USA, with a capacity of around 1.2 billion units.

Srini Pharmaceuticals Pvt. Ltd., was established in 1995. USFDA, TGA and KFDA approved fully integrated global pharmaceutical company, located just about 60 KM's away from the Pharma Capital of India, Hyderabad. Our manufacturing facility has five fully equipped production blocks with most efficient functional utilities with multiple clean rooms having the ability to produce 10 API's at a time, supported by central quality control laborites with all sophisticated instruments by maintaining complete QMS. The state-of-the-Art Research and development laboratory recognized and approved by Department of Science and Technology, Government of India.

Founded in 1997 and headquartered in Zhuhai, China, our company is dedicated to the development, manufacturing, and promotion of cost-effective, high-quality generic drugs and API. Our product line focuses on the fundamental therapeutic areas of Cardiovascular, Gastrointestinal, and CNS. We have been acknowledged for our compliance with cGMP and ICH guidelines by regulatory authorities such as NMPA, USFDA, PMDA, and MFDS (Korea). Zhuhai Rundu Pharmaceutical Co., Ltd. is a contemporary scientific and technological pharmaceutical enterprise that integrates drug research and development, production, and distribution. Situated in Jinwan District, Zhuhai City, Guangdong Province, it was established in 1999 and became publicly listed on the Shenzhen Stock Exchange on January 5, 2018 (stock abbreviation: Rundu; stock code: 002923). The company's primary operations revolve around the research and development, production, and sales of chemical-pharmaceutical preparations, chemical raw materials, and pharmaceutical intermediates.